Treatment of cystic fibrosis in low-income countries

Lancet Respir Med. 2016 Feb;4(2):91-2. doi: 10.1016/S2213-2600(15)00507-X.

Authors

Malena Cohen-Cymberknoh¹, David Shoseyov¹, Oded Breuer¹, Mahmoud Shamali², Michael Wilschanski¹, Eitan Kerem³

Affiliations

¹ CF Center, Hadassah-Hebrew University Medical Center, Jerusalem, POB 12000, Israel.
² CF Center, Gaza strip.
³ CF Center, Hadassah-Hebrew University Medical Center, Jerusalem, POB 12000, Israel. Electronic address: [email protected].

PMID: 26868623
DOI: 10.1016/S2213-2600(15)00507-X

No abstract available

MeSH terms

Anti-Bacterial Agents / economics
Anti-Bacterial Agents / therapeutic use*
Carrier State / drug therapy*
Chest Wall Oscillation / economics
Chest Wall Oscillation / methods*
Cystic Fibrosis / economics
Cystic Fibrosis / therapy*
Delivery of Health Care / economics
Delivery of Health Care / organization & administration
Developing Countries*
Enzyme Replacement Therapy / economics
Enzyme Replacement Therapy / methods*
Humans
Patient Compliance
Pseudomonas Infections / drug therapy*
Respiratory Therapy / economics
Respiratory Therapy / methods
Vitamin A / therapeutic use
Vitamin D / therapeutic use
Vitamin E / therapeutic use
Vitamins / economics
Vitamins / therapeutic use*

Substances

Anti-Bacterial Agents
Vitamins
Vitamin A
Vitamin D
Vitamin E